Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Antibodies, Monoclonal, Humanized
/ administration & dosage
Breast Neoplasms
/ drug therapy
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Humans
Hyperglycemia
/ chemically induced
Lung Neoplasms
/ drug therapy
Meningeal Carcinomatosis
/ drug therapy
Nausea
/ chemically induced
Neoplasm Metastasis
Ovarian Neoplasms
/ drug therapy
Vomiting
/ chemically induced
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
30
08
2019
accepted:
01
05
2020
pubmed:
3
6
2020
medline:
29
10
2020
entrez:
3
6
2020
Statut:
ppublish
Résumé
An increasing fraction of patients with metastatic cancer develop leptomeningeal dissemination of disease (LMD), and survival is dismal
Identifiants
pubmed: 32483359
doi: 10.1038/s41591-020-0918-0
pii: 10.1038/s41591-020-0918-0
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
pembrolizumab
DPT0O3T46P
Banques de données
ClinicalTrials.gov
['NCT02886585']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1280-1284Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : 1R01CA227156-01
Pays : International
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : 5R21CA220253-02
Pays : International
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : 1R01CA244975-01
Pays : International
Commentaires et corrections
Type : ErratumIn
Références
Brastianos, P.K., Brastianos, H. & Eichler, A.F. Leptomeningeal carcinomatosis. in Central Nervous System Metastasis, the Biological Basis and Clinical Consideraiton (ed. Palmieri, D.) 187–201 (Springer, 2013).
Le Rhun, E. et al. Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. J. Neurooncol. 133, 419–427 (2017).
doi: 10.1007/s11060-017-2452-6
Wang, N., Bertalan, M. S. & Brastianos, P. K. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124, 21–35 (2018).
doi: 10.1002/cncr.30911
Grossman, S. A. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol. 11, 561–569 (1993).
doi: 10.1200/JCO.1993.11.3.561
Ongerboer de Visser, B. W. et al. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33, 1565–1572 (1983).
doi: 10.1212/WNL.33.12.1565
Grossman, S. A. & Krabak, M. J. Leptomeningeal carcinomatosis. Cancer Treat. Rev. 25, 103–119 (1999).
doi: 10.1053/ctrv.1999.0119
Little, J. R., Dale, A. J. & Okazaki, H. Meningeal carcinomatosis. Clinical manifestations. Arch. Neurol. 30, 138–143 (1974).
doi: 10.1001/archneur.1974.00490320026003
Lara-Medina, F. et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 18, 233–241 (2012).
doi: 10.1111/j.1524-4741.2012.01228.x
Chamberlain, M. C. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J. Neurooncol. 109, 143–148 (2012).
doi: 10.1007/s11060-012-0880-x
Chuang, T. Y., Yu, C. J., Shih, J. Y., Yang, P. C. & Kuo, S. H. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J. Formos. Med. Assoc. 107, 851–856 (2008).
doi: 10.1016/S0929-6646(08)60201-6
Clamon, G. & Doebbeling, B. Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement. Breast Cancer Res. Treat. 9, 213–217 (1987).
doi: 10.1007/BF01806382
Boyle, R., Thomas, M. & Adams, J. H. Diffuse involvement of the leptomeninges by tumour–a clinical and pathological study of 63 cases. Postgrad. Med. J. 56, 149–158 (1980).
doi: 10.1136/pgmj.56.653.149
Rosen, S. T. et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine 61, 45–53 (1982).
doi: 10.1097/00005792-198201000-00005
El Shafie, R. A. et al. Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome, prognostic factors, and symptom response. Front. Oncol. 8, 641 (2018).
doi: 10.3389/fonc.2018.00641
Glantz, M. J. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394–3402 (1999).
pubmed: 10589750
Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19, 672–681 (2018).
doi: 10.1016/S1470-2045(18)30139-6
Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459–465 (2012).
doi: 10.1016/S1470-2045(12)70090-6
Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722–730 (2018).
doi: 10.1056/NEJMoa1805453
Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976–983 (2016).
doi: 10.1016/S1470-2045(16)30053-5
Wasserstrom, W. R., Glass, J. P. & Posner, J. B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49, 759–772 (1982).
doi: 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7
Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534–e542 (2015).
doi: 10.1016/S1470-2045(15)00088-1
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
doi: 10.1056/NEJMoa1809615
Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 167, 671–686 (2018).
doi: 10.1007/s10549-017-4537-5
Duchnowska, R. et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 18, 43 (2016).
doi: 10.1186/s13058-016-0702-8
Chamberlain, M. C. Leptomeningeal metastasis. Semin. Neurol. 30, 236–244 (2010).
doi: 10.1055/s-0030-1255220
Gani, C. et al. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther. Onkol. 188, 148–153 (2012).
doi: 10.1007/s00066-011-0025-8
Waki, F. et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J. Neurooncol. 93, 205–212 (2009).
doi: 10.1007/s11060-008-9758-3
Hendriks, L. E. L. et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur. J. Cancer 116, 182–189 (2019).
doi: 10.1016/j.ejca.2019.05.019